We effectively determine the antimicrobial activity of your experimental products in our high-throughput, cost-effective models.
- Overprescription and overuse have contributed to rising levels of pathogens resistant to the current arsenal of antimicrobial products. Biofilms, composed of bacteria and/or fungi that have settled on a surface and secreted a protective matrix, also contribute to antimicrobial resistance.
- A critical step in the drug-development process is testing antimicrobial properties. At Extherid Biosciences, we use our predictive models to test experimental products and ensure that the lead candidates perform well in clinical trials.
- Our porcine mucosal model (PMM) is an excellent indicator of clinical success. This model provides an exemplary and cost-effective growth medium for bacteria and allows for testing at the surface-air interface, which more closely reflects actual-use conditions.
- Our highly reproducible PMM functions as an antimicrobial efficacy litmus test to rapidly screen multiple experimental products. We can then maximize the likelihood of clinical success by transitioning the lead candidates into human skin models.
- We are able to further simulate clinical testing with our human skin models. We can test the efficacy of antimicrobial products on both unwounded and wounded human skin models.
- If your formulation is designed to be used on large areas of skin (>10m2; e.g, skin preparation solutions for surgery), we use the cup-scrub method (also known as the cylinder sampling method) in accordance with American Society for Testing and Materials (ASTM) International E2897 – 12(2017).
- Our models enable efficacy testing against planktonic pathogens as well as those embedded in biofilms. These models are highly customizable. If your current options for infectious disease testing are insufficient, contact us and we will determine how we can best help you achieve your goals.